Akebia to Showcase Phase 2 FSGS, Basket Trials and Phase 1 AKB-9090 on April 2
Akebia Therapeutics will host a virtual R&D Day on April 2, 2026 to present Phase 2 praliciguat for FSGS and AKB-097 Phase 2 basket trial in IgA nephropathy, lupus nephritis and C3 glomerulopathy. It will also cover Phase 1 initiation of HIF-PH inhibitor AKB-9090 in acute kidney injury.
1. Virtual R&D Day Overview
Akebia will host a virtual R&D Day on April 2, 2026 at 10:00 AM EDT. Management and scientific experts James Tumlin, V. Michael Holers and Jonathan Barratt will review the kidney disease pipeline, unmet needs and treatment landscape, followed by a live Q&A session.
2. Phase 2 Praliciguat in FSGS
Praliciguat, a soluble guanylate cyclase stimulator, is advancing in a Phase 2 trial targeting focal segmental glomerulosclerosis (FSGS). The presentation will highlight its mechanism of action, supporting data and differentiation versus existing therapies.
3. AKB-097 Phase 2 Basket Trial
AKB-097 is a next-generation tissue-targeted complement inhibitor planned for a Phase 2 basket trial in H2 2026. It will enroll patients with IgA nephropathy, lupus nephritis and C3 glomerulopathy to assess safety, dosing and preliminary efficacy.
4. Phase 1 AKB-9090 in AKI
AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, is slated for a Phase 1 trial in acute kidney injury associated with cardiac surgery in H1 2026. The R&D Day will outline study design, biomarker endpoints and development milestones.